Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
![]()
Reuters NewMedia - Thursday November 18, 1999
Only one kit is approved for home use, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) said in a statement. That is the "Home Access Express HIV-1 Test System," made by Home Access Health Corp.
"The approved HIV test has been carefully reviewed by the FDA to ensure that the test system is capable of yielding accurate, dependable results," Steven Masiello of the FDA's Center for Biologics Evaluation and Research, said in a statement.
"The consumer has no assurance of the reliability or accuracy of the test results from unapproved HIV home test kits."
Many of the kits are sold on the Internet, the FDA said. "The Internet makes it easy for con artists to take advantage of consumers," Dr. Jane Henney, commissioner of the FDA, said in a statement. "Therefore, consumers need to be cautious."
The FTC said it had taken action against the maker of one unapproved kit, Cyberlinx Marketing Inc., and reached a settlement.
"Cyberlinx's egregious conduct threatened the health of those consumers who relied upon the representation that the kits gave accurate results," Jodie Bernstein, director of the FTC's Bureau of Consumer Protection, said in a statement.
"Cyberlinx and its president, Jeffrey S. Stein, have settled FTC charges that their unapproved HIV home test kits gave erroneous results," the FTC added in the statement.
"Under the stipulated final order settling the charges, Cyberlinx and Stein are banned from marketing any HIV home test kits in the future and must pay back the money they received from the sale of their kits," the statement added.
They were banned for life from marketing any HIV home test kit, and must post a bond to the FTC if they want to sell any medical device ever again. Another kit, the Confide HIV Testing Service made by Direct Access Diagnostics, had FDA approval but is no longer on the market.
991118
RE991106
Copyright © 1999 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .